Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HILL INTEREST IN OVULEN COUNTERFEITING MAY EXPAND

Executive Summary

HILL INTEREST IN OVULEN COUNTERFEITING MAY EXPAND to an investigation of Rx drug pricing differentials -- especially the spread between HMO bid prices and levels to retail pharmacies. Rep. Dingell's (D-Mich.) Commerce/Oversight Subcmte. started investigating pharmaceutical counterfeiting last November in the wake of widespread forgery of Searle's Ovulen 21 birth control pills. The investigation began with a survey sent to pharmaceutical mfrs. asking for more information on the industry's experience with counterfeiters over the past five years ("The Pink Sheet" Nov. 26, T&G-2). Because of the intense price competition in the oral contraceptive market, the area is ripe for further investigation of differentials, beyond the counterfeiting issue. A hearing on the Ovulen situation per se could be difficult to arrange at this time since the source of the counterfeit contraceptives is still under investigation.

HILL INTEREST IN OVULEN COUNTERFEITING MAY EXPAND to an investigation of Rx drug pricing differentials -- especially the spread between HMO bid prices and levels to retail pharmacies. Rep. Dingell's (D-Mich.) Commerce/Oversight Subcmte. started investigating pharmaceutical counterfeiting last November in the wake of widespread forgery of Searle's Ovulen 21 birth control pills. The investigation began with a survey sent to pharmaceutical mfrs. asking for more information on the industry's experience with counterfeiters over the past five years ("The Pink Sheet" Nov. 26, T&G-2).

Because of the intense price competition in the oral contraceptive market, the area is ripe for further investigation of differentials, beyond the counterfeiting issue. A hearing on the Ovulen situation per se could be difficult to arrange at this time since the source of the counterfeit contraceptives is still under investigation.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS007804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel